...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >First report of improvement of coeliac disease in a patient with Sj?gren's syndrome treated with rituximab.
【24h】

First report of improvement of coeliac disease in a patient with Sj?gren's syndrome treated with rituximab.

机译：第一次改善SJ患者腹腔疾病的报告？GREN综合征用Rituximab治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glucocorticosteroids (GCs) have been employed extensively for the treatment of rheumatoid arthritis (RA) and other autoimmune and systemic inflammatory disorders. Their use is supported by extensive literature and their utility is reflected in their incorporation into current treatment guidelines for RA and other conditions. Nevertheless, there is still some concern regarding the long-term use of GCs because of their potential for clinically important adverse events, particularly with an extended duration of treatment and the use of high doses. This article systematically reviews the efficacy for radiological and clinical outcomes for low-dose GCs (defined as ≤10 mg/day prednisone equivalent) in the treatment of RA. Results reviewed indicated that low-dose GCs, usually administered in combination with synthetic DMARDs, most often MTX, significantly improve structural outcomes and decrease symptom severity in patients with RA. Safety data indicate that GC-associated adverse events are dose related, but still occur in patients receiving low doses of these agents. Concerns about side effects associated with GCs have prompted the development of new strategies aimed at improving safety without compromising efficacy. These include altering the structure of existing GCs and the development of delayed-release GC formulations so that drug delivery is timed to match greatest symptom severity. Optimal use of low-dose GCs has the potential to improve long-term outcomes for patients with RA.
机译：糖皮质激素（GCS）已经广泛用于治疗类风湿性关节炎（RA）和其他自身免疫和全身炎症障碍。他们的使用得到了广泛的文学支持，他们的效用反映在他们纳入目前的RA和其他条件的治疗准则中。然而，由于临床上重要不良事件的可能性，特别是临床重要不良事件的可能性，仍然存在一些关注的GCS，特别是在延长持续时间和高剂量的使用。本文系统地审查了RA治疗中低剂量GCs（定义为≤10mg/天泼尼松等当量）的放射性和临床结果的疗效。结果表明，低剂量GCs，通常与合成DMARD组合施用，最常是MTX，显着提高了RA患者的结构性结果并降低症状严重程度。安全数据表明，GC相关不良事件是相关的，但仍然发生在接受这些药剂的低剂量的患者中。关于与GCS相关的副作用的担忧促使旨在改善安全性的新策略，而不会影响疗效。这些包括改变现有GCS的结构以及延迟释放GC制剂的发展，以便试论药物递送以匹配最大的症状严重程度。低剂量GCs的最佳用途具有可改善RA患者的长期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号